MiR-29 Induces K562 Cell Apoptosis by Down-Regulating FoxM1

Xiaofang Wang
Hua Zhong
Lei Wang
Yuqian Dong
Ankui Jia
Qingjiang Mo
Chenguang Zhang

Background: Leukemia seriously threatens human life and health. MicroRNAs can regulate cell growth, proliferation, and death. This article investigated the role of miR-29 on regulating leukemia cell growth, proliferation, and apoptosis.

Material/Methods: miR-29 and scramble miRNA were transfected to K562 cells. MTT assay, colony formation assay, caspase-3 activity detection, and flow cytometry were applied to test miR-29 effect on cell growth, proliferation, and apoptosis. Western blot was used to detect Forkhead box protein M1 (FoxM1) protein expression. After we transfected miR-29, K562 cells were transfected with FoxM1 siRNA to test cell apoptosis.

Results: K562 cell growth and proliferation were inhibited after transfection with miR-29. Apoptosis phenotype and caspase-3 activation were observed. FoxM1 level decreased. SiRNA FoxM1 enhanced miR-29-induced K562 cell apoptosis. FoxM1 overexpression suppressed miR-26-induced K562 cell apoptosis.

Conclusions: MiR-29 restrained K562 cell growth and proliferation. MiR-29 induced K562 cell apoptosis through down-regulating FoxM1.

MeSH Keywords: Amlodipine • Buthionine Sulfoximine • K562 Cells

Full-text PDF: http://www.medscimonit.com/abstract/index/idArt/894554

Source of support: Departmental sources
Background

Leukemia is caused by several factors, including genetic, viral, chemical, and radiation factors. Leukemia has become the sixth leading cause of death among all cancers [1]. Currently, the main treatments for leukemia are radiotherapy, chemotherapy, stem cell transplantation, molecular target therapy, and immune therapy [2]. Although various therapies are available, molecular-targeted therapy is applicable to almost all types of leukemia. Leukemia-targeted therapy focuses on protein or other molecules closely related to occurrence and development. At present, there are few targets for leukemia therapy. Therefore, in this study we explored potential targets for leukemia-targeted therapy from the cellular level.

Material and Methods

Reagents and cell line

3-(4, 5-dimethyl-2-thiazolyl)-2, 5-diphenyl-2-H-tetrazolium bromide (MTT) was purchased from Beyotime Biotechnology Co. FoxM1 plasmid was from the plasmid library in our laboratory. FoxM1 primary antibody and horseradish peroxidase-labeled secondary antibody were from Sigma. GAPDH primary antibody was bought from Cell Signaling. Cell culture medium RPMI-1640 and the fetal bovine serum were purchased from Santa Cruz. K562 cells were provided by the American type culture collection (ATCC). RNA extraction and reverse transcription RT-PCR kit was purchased from Beijing Dingguo Changsheng Biotechnology Co., LTD. FITC-Annexin V and caspase 3 activity detection kits were from Beyotime Biotechnology Research Institute. MiR-29 and scramble miRNA were designed and produced by Sangon.

Cell culture

K562 cells were maintained in RPMI-1640 medium supplemented with 10% fetal calf serum in a humid atmosphere containing 5% CO2 at 37°C [9].

MTT assay

K562 cell growth and viability were detected by MTT assay according to the literature [10]. Cells were seeded in 12-well plates at a density of 8×10⁴ cells/well and incubated for 72 h at 37°C. After addition of 5 mg/ml MTT to each well, plates were incubated for 6 h at 37°C. Another 100 μl DMSO was added and absorbance of each well at 492 nm was read using a spectrophotometer [11].

Colony formation assay

K562 cell colony formation ability was measured according to the literature [12]. Cells were plated in soft agar at different cell numbers and cultured for 12 days. The colonies were stained with Giemsa for 30 min after fixation with 10% formaldehyde for 30 min.

Transfection

K562 cells were seeded into 96-well plates. We transfected 150 nM FoxM1 siRNA (sequence: 5′-GGTTGTTAGATTACTCC-3′, 5′-TGATAAGATGGCCCTTCTC-3′) or miR-29 to cells by using Lipo2000. K562 cells were maintained in RPMI-1640 medium supplemented with 10% fetal calf serum in a humid atmosphere containing 5% CO2 at 37°C [9].

Thus, the aim of this study was to explore the effect of miR-29 on K562 cell growth, proliferation, and apoptosis.
Flow cytometry: Cells were incubated at Annexin-V-FITC combining buffer at $1 \times 10^5$ cells. Flow cytometry was used to detect apoptosis of the transfected K562 cells at 488 nm by determining the relative amount of Annexin V-FITC-positive cells [14].

**Western blot**

The cells were harvested and homogenized with lysis buffer. Total protein was separated by denaturing 10% SDS – polyacrylamide gel electrophoresis and FoxM1 protein level was detected [15].

**Caspase-3 activity assay**

K562 cells caspase-3 activity was determined according to the manual [16]. The cells were harvested and resuspended in RIPA. The cells were incubated for 60 min at 37°C after adding 2 mM Ac-DEVD-pNA. Absorbance of each well at 492 nm was read using a spectrophotometer [17].

**Statistical analysis**

All statistical analyses were performed using SPSS13.0 software. Numerical data are presented as means and standard deviation. Differences between multiple groups were analyzed by one-way ANOVA. $P < 0.05$ was considered as a significant difference.

## Results

**MiR-29 transfection inhibited K562 cells growth**

As shown in Figure 1, 1 µg miR-29 transfection restrained K562 cells growth significantly ($P=0.0012$), while cells growth presented no obvious difference when transfected with miRNA, so we omitted the non-transfection group in the following experiments.

**MiR-29 transfection suppressed K562 cells proliferation**

Colony formation assay showed that 1 µg miR-29 transfection obviously suppressed K562 colony formation ability compared with the miRNA transfection group ($P=0.029$) (Figure 2).

**MiR-29 transfection induced K562 cell apoptosis**

Flow cytometry revealed that phosphatidylserine eversion level increased significantly after transfection with 1 µg miR-29 ($P=0.0024$) (Figure 3).

**MiR-29 transfection induced caspase-3 activation in K562 cells**

Caspase-3 activity degree increased markedly after transfection with 1 µg miR-29 ($P=0.012$) (Figure 4).

**MiR-29 transfection decreased FoxM1 protein level**

Western blot analysis showed that 1 µg miR-29 transfection decreased FoxM1 protein level (Figure 5).

**FoxM1 knockdown enhanced miR-29 induced K562 cell apoptosis**

Phosphatidylserine eversion suggested that after FoxM1 knockdown by siRNA, 0.1 µg miR-29-induced K562 cell apoptosis increased significantly ($P=0.0053$) (Figure 6).
FoxM1 overexpression inhibited miR-29 induced cell apoptosis

Flow cytometry indicated that after FoxM1 plasmid was transfected, 1 μg miR-29 induced K562 cell apoptosis decreased obviously (P=0.0029) (Figure 7).

Discussion

MiRNAs play a role in tumorigenesis and development, which has significance for tumor diagnosis and treatment. In this study, we investigated the regulating effect of miR-29 on K562 cells and its possible mechanism. The results showed that miR-29 overexpression inhibits human leukemia K562 cells growth and proliferation, and promotes K562 cells apoptosis, which is consistent with previous results [5].

FoxM1 is a conservative transcription factor that can mediate cell growth, proliferation, and apoptosis through regulating gene expression [18]. At present, whether FoxM1, synergistically or antagonistically with miRNAs, can regulate K562 cells growth and apoptosis has not yet been determined [19,20]. The results showed that miR-29 overexpression down-regulated FoxM1 expression level. FoxM1 knockdown enhanced miR-29 transfection-induced K562 cells apoptosis. FoxM1 overexpression inhibited cell apoptosis caused by miR-29. MiR-29 activating Caspase-3 in K562 cells suggests that miR-29 induces K562 cell apoptosis.
Many miRNAs are believed to act as tumor suppressors, although the evidence supporting those claims is merely correlative. Substantial experimental data are lacking, and miRNA knockout mice that develop or are predisposed to cancer have not been yet reported. It is noteworthy that most of the miRNAs with a clear tumor suppressor role (miR-15- a/16-1, miR-29s, and let-7) have more than 1 genomic location, and although they are transcribed from different precursors, the mature miRNA is identical. The different loci could be differentially regulated; for example, in HeLa cells the mature miR-29b is preferentially transcribed from the miR-29b-1/miR-29a locus in chromosome 7q32, whereas the other locus, miR-29b-2/miR-29c in chromosome 1q23, is silenced.

This study has 3 limitations: (1) the lack of clinical leukemia specimens at different development stages. Western blot detection of FoxM1 protein expression in leukemia and normal tissue level could reveal the relationship between FoxM1 level and leukemia progression; (2) the lack of clinical specimens using different chemotherapy drugs. Western blot detection of FoxM1 protein in leukemia and normal tissue can further determine their relationship; and (3), the lack of a leukemia rat animal model treated with miR-29, which can explore the effect of miR-29 in leukemia treatment from the animal level and provide information for clinical practice.

Conclusions

Our results revealed that miR-29 transfection can inhibit K562 cells growth and proliferation. MiR-29 induced K562 cells apoptosis through down-regulating FoxM1. FoxM1 might be a potential target for killing tumor cells.

References:

1. Napier RI, Norris BA, Swimm A et al: Low doses of imatinib induce myeloid and increase host anti-microbial immunity. PLoS Pathog, 2015; 11: e1004770
2. Chendamarai E, Ganesan S, Alex AA et al: Comparison of newly diagnosed and relapsed patients with acute promyelocytic leukemia treated with arsenic trioxide: insight into mechanisms of resistance. PLoS One, 2015; 10: e0121912
3. Yang FQ, Zhang HM, Chen SJ et al: MiR-506 is down-regulated in clear cell renal cell carcinoma and inhibits cell growth and metastasis via targeting FLOT1. PLoS One, 2015; 10: e0120258
4. Wang G, Sun Y, He Y et al: MicroRNA-338-3p inhibits cell proliferation in hepatocellular carcinoma by target forkhead box P4 (FOXP4). Int J Clin Exp Pathol, 2015; 8: 337-44
5. Jimenez-Hernandez E, Duenas-Gonzalez MT, Arellano-Galindo J et al: Survival of Mexican children with acute myeloid leukemia who received early intensification chemotherapy and an autologous transplant. Biomed Res Int, 2015; 2015: 940278
6. Duhachek-Muggy S, Zolkiewska A: ADAM12-L is a direct target of the miR-29 and miR-200 families in breast cancer. BMC Cancer, 2015; 15: 93
7. Bicknell KA, Forkhead (FOX) transcription factors and the cell cycle: measurement of DNA binding by FoxO and FoxM transcription factors. Methods Mol Biol, 2005; 296: 247-62
8. Xu X, Chen W, Miao R et al: miR-34a induces cellular senescence via modulation of telomerase activity in human hepatocellular carcinoma by targeting FOXM1/c-Myc pathway. Oncotarget, 2015; 6: 3988-4004
9. Nurhayati RW, Ojima Y, Nomura N, Taya M: Promoted megakaryocytic differentiation of K562 cells through oxidative stress caused by near ultraviolet irradiation. Cell Mol Biol Lett, 2014; 19: 590-600
10. Rahimi R, Mahdavi M, Pejman S et al: Inhibition of cell proliferation and induction of apoptosis in K562 human leukemia cells by the derivative (3-NpC) from dihydro-pyranochromenes family. Acta Biochim Pol, 2015; 62: 83-88
11. Ghasemian M, Mahdavi M, Zare P et al: Spiroquazilazolindine-induced cytotoxicity and apoptosis in K562 human leukemia cells by the derivative (3-NpC) from dihydro-pyranochromenes family. Acta Biochim Pol, 2015; 62: 83-88
12. Eide CA, Adrian LT, Tyner JW et al: The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABL1T315I and exhibits a narrow resistance profile. Cancer Res, 2011; 71: 3189-95
13. Zhu XS, Lin ZY, Du J et al: BCR/ABL miRNA targeting small interfering RNA effects on proliferation and apoptosis in chronic myeloid leukemia. Asian Pac J Cancer Prev, 2014; 15: 4773-80
14. Smolarek D, Haftt C, Buczowska A et al: Studies of a murine monoclonal antibody directed against DARC: reappraisal of its specificity. PLoS One, 2015; 10: e0116472
15. Liu Y, Yang H, Song Z, Gu S: Copper excess in liver HepG2 cells interferes with apoptosis and lipid metabolic signaling at the protein level. Turk J Gastroenterol, 2014; 25: S116–21
16. Zhang W, Zhao L, Liu J et al: Cisplatin induces platelet apoptosis through the ERK signaling pathway. Thromb Res, 2012; 130: 81–91
17. Zhang W, Liu J, Sun R et al: Calpain activator dibucaine induces platelet apoptosis. Int J Mol Sci, 2011; 12: 2125–37
18. Liu Y, Chen X, Gu Y et al: FOXM1 overexpression is associated with cisplatin resistance in non-small cell lung cancer and mediates sensitivity to cisplatin in A549 cells via the JNK/mitochondrial pathway. Neoplasma, 2015; 62: 61–71
19. Zhou M, Zeng J, Wang X et al: MiR-370 sensitizes chronic myeloid leukemia K562 cells to homoharringtonine by targeting Forkhead box M1. J Transl Med, 2013; 11: 265
20. Zhang X, Zeng J, Zhou M et al: The tumor suppressive role of miRNA-370 by targeting FoxM1 in acute myeloid leukemia. Mol Cancer, 2012; 11: 56